Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/4/2024 | $52.00 | Outperform → Neutral | Wedbush | |
| 3/25/2024 | $50.00 → $75.00 | Hold → Buy | Loop Capital | |
| 1/18/2024 | $41.00 → $61.00 | Neutral → Overweight | Piper Sandler | |
| 12/8/2023 | $45.00 | Outperform → Market Perform | TD Cowen | |
| 11/20/2023 | $25.00 | Neutral | JP Morgan | |
| 9/28/2023 | $33.00 | Overweight | Piper Sandler | |
| 8/3/2023 | $36.00 → $31.00 | Buy → Neutral | BofA Securities | |
| 5/4/2023 | $30.00 | Equal Weight → Overweight | Wells Fargo |
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
Wedbush downgraded Tempur Sealy Int'l from Outperform to Neutral and set a new price target of $52.00
Loop Capital upgraded Tempur Sealy Int'l from Hold to Buy and set a new price target of $75.00 from $50.00 previously
Piper Sandler upgraded Tempur Sealy Int'l from Neutral to Overweight and set a new price target of $61.00 from $41.00 previously
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
LEXINGTON, Ky., Nov. 7, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", )) today announced that its Board of Directors has declared a fourth quarter cash dividend on its common stock of $0.13 per share. The dividend is payable on December 5, 2024, to shareholders of record as of November 21, 2024. About Tempur Sealy International, Inc.Tempur Sealy is committed to improving the sleep of more people, every night, all around the world. As a leading designer, manufacturer, distributor and retailer of bedding products worldwide, we know how crucial a good night of sleep is to overall health and wellness. Utilizing over a century of knowledge and
- Consolidated Sales Growth of 2%- Consolidated Gross Margins Expands- EPS Growth of 14% and Adjusted EPS(1) Growth of 7%- Robust Third Quarter Cash Flow from Operations of $257 Million LEXINGTON, Ky., Nov. 7, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX) announced financial results for the third quarter ended September 30, 2024 and narrowed financial guidance for the full year 2024. THIRD QUARTER 2024 FINANCIAL SUMMARY Total net sales increased 1.8% to $1,300.0 million as compared to $1,277.1 million in the third quarter of 2023, with a decrease of 0.8% in the North America business segment and an increase of 12.4% in the International business segment. On a constant cur
#1 in Customer Satisfaction for both Mattresses Purchased In-Store and Online for 2024* LEXINGTON, Ky., Nov. 6, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", )), the company synonymous with innovation in the mattress industry, today announced that its Tempur-Pedic® brand was ranked #1 in Customer Satisfaction for Mattresses Purchased In-Store in the J.D. Power 2024 U.S. Mattress Satisfaction Study*, marking the fifth time in six years the Company has won the award. Additionally, for the fourth consecutive year, the brand is also ranked #1 in Customer Satisfaction for the Online Purchase segment. With the 2024 study results, Tempur-Pedic is
Wedbush analyst Seth Basham reiterates Tempur Sealy Intl (NYSE:TPX) with a Outperform and maintains $55 price target.
In the last three months, 7 analysts have published ratings on Tempur Sealy Intl (NYSE:TPX), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 Analysts have recently evaluated Tempur Sealy Intl and provided 12-month price targets. The average target is $64.0, accompanied by a high estimate of $66.00 and a low estimate of $58.00. Experiencing a
10-Q - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Filer)
8-K - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Filer)
8-K - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Filer)
LEXINGTON, Ky., Nov. 7, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", )) today announced that its Board of Directors has declared a fourth quarter cash dividend on its common stock of $0.13 per share. The dividend is payable on December 5, 2024, to shareholders of record as of November 21, 2024. About Tempur Sealy International, Inc.Tempur Sealy is committed to improving the sleep of more people, every night, all around the world. As a leading designer, manufacturer, distributor and retailer of bedding products worldwide, we know how crucial a good night of sleep is to overall health and wellness. Utilizing over a century of knowledge and
- Consolidated Sales Growth of 2%- Consolidated Gross Margins Expands- EPS Growth of 14% and Adjusted EPS(1) Growth of 7%- Robust Third Quarter Cash Flow from Operations of $257 Million LEXINGTON, Ky., Nov. 7, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX) announced financial results for the third quarter ended September 30, 2024 and narrowed financial guidance for the full year 2024. THIRD QUARTER 2024 FINANCIAL SUMMARY Total net sales increased 1.8% to $1,300.0 million as compared to $1,277.1 million in the third quarter of 2023, with a decrease of 0.8% in the North America business segment and an increase of 12.4% in the International business segment. On a constant cur
LEXINGTON, Ky., Oct. 15, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX) will release its financial results for the third quarter ended September 30, 2024, before the NYSE opening of regular trading on Thursday, November 7, 2024. The Company will hold a conference call at 8:00 a.m. Eastern Time. The call will be webcast and can be accessed on the Company's investor relations website at investor.tempursealy.com. After the conference call, a webcast replay will remain available on the website for 30 days. About the CompanyTempur Sealy is committed to improving the sleep of more people, every night, all around the world. As a leading designer, manufacturer, distributor, and re
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward." "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver. Ms.
Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. "I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry," said Ron Renaud, president and chie
Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. "We are excited to welcome Susan to Cerevel, as she brings a breadth of experience leading biopharmaceutical companies by leveraging her strategic understanding, f
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)